모르핀 의약품 시장 규모 : 제형별, 용도별, 유통 채널별, 최종 용도별, 예측(2024-2032년)

Global Morphine Drugs Market will witness over 6.5% CAGR from 2024 to 2032. Morphine's pivotal role in palliative care significantly spurs the demand. As palliative care services expand globally, morphine emerges as a cornerstone in managing end-of-life pain and enhancing patients' quality of life. Its efficacy in alleviating severe pain makes it indispensable in providing comfort and relief for terminally ill individuals. This growing emphasis on palliative care highlights the importance of pain management in healthcare. It amplifies the need for accessible and effective opioid medications like morphine, ensuring dignified and compassionate end-of-life care for patients globally.

The competitive landscape in the market is characterized by several key morphine drug producers focusing on pharmaceutical production and distribution. Companies such as Purdue Pharma, Johnson & Johnson, and Mallinckrodt Pharmaceuticals dominate the market with their extensive product portfolios and global market reach. These manufacturers compete based on product efficiency, regulatory adherence, safety profiles, and developments in drug delivery technologies to meet the demands of healthcare vendors and patients requiring pain management solutions.

The overall morphine drugs market is classified based on dosage form, distribution channel, application, end-use, and region.

The oral segment will experience prominent CAGR expansion through 2032. Advancements in oral drug delivery technology have enhanced the efficacy and convenience of administering morphine, making it more accessible for patients requiring long-term pain management. Additionally, the increasing prevalence of chronic pain conditions globally has spurred greater prescription rates for oral morphine formulations. Moreover, heightened awareness among healthcare providers about the benefits of oral morphine in balancing pain relief and patient safety has contributed to its growing adoption in clinical practice, escalating its demand in the oral drug segment.

The palliative care segment will garner a significant morphine drugs market share by 2032, owing to its crucial role in managing severe pain associated with terminal illnesses. As palliative care gains recognition for improving the quality of life in end-stage diseases, morphine's effectiveness in alleviating pain and enhancing comfort has become indispensable. Healthcare providers increasingly rely on morphine to ensure dignified end-of-life care by providing relief from physical suffering. This trend is reinforced by evolving healthcare policies and guidelines that prioritize pain management as an integral component of holistic patient care, driving the demand for morphine in palliative settings.

The CAGR for the Asia Pacific morphine drugs market will be optimistic through 2032. Increasing incidences of chronic diseases and cancer-related pain are ushering in the need for effective pain management solutions like morphine. Moreover, improvements in healthcare infrastructure and rising healthcare expenditures in the Asia Pacific are facilitating greater access to pain relief medications. As awareness about palliative care increases in the region, there is a growing acceptance and adoption of morphine as a crucial component in managing end-of-life pain and improving patient comfort, boosting its demand.

Table of Contents

Chapter 1 Methodology & Scope

• 1.1 Market scope & definitions
• 1.2 Research design
  • 1.2.1 Research approach
  • 1.2.2 Data collection methods
• 1.3 Base estimates & calculations
  • 1.3.1 Base year calculation
  • 1.3.2 Key trends for market estimation
• 1.4 Forecast model
• 1.5 Primary research and validation
  • 1.5.1 Primary sources
  • 1.5.2 Data mining sources

Chapter 2 Executive Summary

• 2.1 Industry 360° synopsis

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Increasing prevalence of chronic pain conditions
    • 3.2.1.2 Growing awareness of palliative care
    • 3.2.1.3 Technological advancements in drug formulations
    • 3.2.1.4 Rising number of surgical procedures
  • 3.2.2 Industry pitfalls & challenges
    • 3.2.2.1 Risk of adverse effects and overdose
    • 3.2.2.2 Concerns about opioid addiction and abuse
• 3.3 Growth potential analysis
• 3.4 Regulatory landscape
• 3.5 Pipeline analysis
• 3.6 Porter's analysis
• 3.7 PESTEL analysis
• 3.8 Future market trends

Chapter 4 Competitive Landscape, 2023

• 4.1 Introduction
• 4.2 Company matrix analysis
• 4.3 Competitive analysis of major market players
• 4.4 Competitive positioning matrix
• 4.5 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Dosage Form, 2021 - 2032 ($ Mn)

• 5.1 Key trends
• 5.2 Injectable
• 5.3 Oral
• 5.4 Other dosage forms

Chapter 6 Market Estimates and Forecast, By Application, 2021 - 2032 ($ Mn)

• 6.1 Key trends
• 6.2 Pain management
  • 6.2.1 Cancer pain
  • 6.2.2 Neuropathic pain
  • 6.2.3 Osteoarthritis pain
  • 6.2.4 Other pain managements
• 6.3 Palliative care
• 6.4 Diarrhea suppressant
• 6.5 Anesthesia
• 6.6 Cold & cough suppressant
• 6.7 Other applications

Chapter 7 Market Estimates and Forecast, By Distribution Channel, 2021 - 2032 ($ Mn)

• 7.1 Key trends
• 7.2 Hospital pharmacy
• 7.3 Retail pharmacy
• 7.4 Online pharmacy

Chapter 8 Market Estimates and Forecast, By End-Use, 2021 - 2032 ($ Mn)

• 8.1 Key trends
• 8.2 Hospitals and clinics
• 8.3 Ambulatory surgical centers
• 8.4 Other end-users

Chapter 9 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)

• 9.1 Key trends
• 9.2 North America
  • 9.2.1 U.S.
  • 9.2.2 Canada
• 9.3 Europe
  • 9.3.1 Germany
  • 9.3.2 UK
  • 9.3.3 France
  • 9.3.4 Spain
  • 9.3.5 Italy
  • 9.3.6 Netherlands
  • 9.3.7 Rest of Europe
• 9.4 Asia Pacific
  • 9.4.1 China
  • 9.4.2 Japan
  • 9.4.3 India
  • 9.4.4 Australia
  • 9.4.5 South Korea
  • 9.4.6 Rest of Asia Pacific
• 9.5 Latin America
  • 9.5.1 Brazil
  • 9.5.2 Mexico
  • 9.5.3 Argentina
  • 9.5.4 Rest of Latin America
• 9.6 Middle East and Africa
  • 9.6.1 South Africa
  • 9.6.2 Saudi Arabia
  • 9.6.3 UAE
  • 9.6.4 Rest of Middle East and Africa

Chapter 10 Company Profiles

• 10.1 Alcaliber S.A.
• 10.2 Daiichi Sankyo Company Limited
• 10.3 Hikma Pharmaceuticals PLC
• 10.4 Mallinckrodt plc
• 10.5 Pfizer Inc.
• 10.6 Purdue Pharma L.P.
• 10.7 Sandoz AG
• 10.8 Taj Pharmaceuticals Limited
• 10.9 Verve Health Care Ltd.
• 10.10 Viatris Inc.